Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
tiab is the ultimate PERCENT...eom
I won't be walking near short buildings before this story ends.. Go CTIX
I see the Dow under 10000 minimum... eom
Fidelity Assets Tech And Sinclair Securities.. eom
Whatever happened to the bio-film testing with that big medical device company. The outbreaks happening in California hospitals this week would seem like a opportunity for CTIX. Maybe the next person to get the personnel tour could ask about this forgotten aspect of the company.
A Los Angeles-area hospital said Wednesday that some of its patients contracted an antibiotic-resistant "superbug" that has been linked to a type of medical scope and infected dozens of people around the country.
Huntington Memorial Hospital said in a statement that it notified public health authorities after several patients who had procedures using Olympus Corp. duodenoscopes were found to have the resistant pseudomonas bacteria.
The hospital said it has quarantined the scopes while it investigates whether they may be linked to the infections.
The statement made no mention of the total number of infected patients or their conditions.
However, the Los Angeles Times said ( http://lat.ms/1J5p3pl ) the problem was discovered in June and three patient infections have been reported to health officials.
Drug-resistant bacterial infections around the country have been linked to contamination of the reusable scopes, which are used for a procedure known as endoscopic retrograde cholangiopancreatography. The fiber-optic scopes are placed down a patient's throat and used to diagnose and treat gallstones, blockages and cancers of the digestive tract.
"The patients who experienced the bacterial growth were very ill before they underwent the scope procedure, and the risk of the procedure was explained to each patient and family," Huntington Memorial's statement said.
A dozen infections were reported earlier this year at Cedars-Sinai and UCLA's Ronald Reagan medical centers in Los Angeles. Three patients died.
The hospitals said the infections occurred even though the devices had been cleaned to the manufacturer's standards. They have since implemented more stringent disinfection procedures.
Olympus is the market leader for duodenoscopes in the U.S., accounting for about 85 percent of sales, according to the U.S. Food and Drug Administration.
On Monday, the FDA posted a warning letter online that said Olympus waited three years to alert regulators to a cluster of 16 infections in patients who underwent procedures using the scope in 2012.
Additionally, FDA inspectors found that the company has no standard procedure for promptly reporting serious problems with its devices, a requirement for medical device companies.
The company said it was reviewing the FDA's warning.
The FDA also posted warning letters Monday to two other scope manufacturers citing problems with the testing, design, reporting and quality control of their devices.
What happens if this B-OM trial is successful ? Can it go straight to production as a revenue producer or will they have months on evaluation on this trial and then have a ph 3 study with more months of evaluation while people suffer.
Give em hell Dr J..eom
Damn I want a CTIX baseball hat
Bless you , youssef. Thank you
Btw, we are GREEN
There's a hard core agenda in play here. What for ?..eom
My wife and I will both file complaints. Thanks for the info..eom
This stock will drive you to drink
Mostly to celebrate and once in a while to shake off the shock like yesterday that was caused by that BS article.
I hope that CTIX comes up with a cure for liver damage...
Partnership NEWS
coming soon.
7.32 by Dec 31st or better
Last one out turn off the lights
Site down on my tablet. Error in database connection.
We might get news tomorrow, Georgejji hasn't posted his death notice to expect great news.
The POST of the year. Long term patience instead of short term panic thinking.
Look at the yearly charts. Last year I was making my major buys at 1.60- 1.70 range.
The science is much further along than 11 months ago and will get rewarded in due time as it has been over the years. The O/S is low with a 40% owned by insiders.
Let Leo do his thing. He's put far more money into peoples wallets than any of the whiners ever will.
Damn, that stinks. I actually was expecting news tomorrow. That's out of the question now.
R/S nonsense buried by CEO. New talking point nonsense, the reverse merger garbage.
Good night, sleep tight
Don't let the reverse merger bite.
Newbies: CEO states twice that R/S will NOT happen, NO WAY , NO HOW, PERIOD...eom
Cliffhanger funny. Good one
Really ? LOL..eom
Dear Leo
Stay true to your word about NEVER reverse splitting. Don't listen to members of the " Chart dude gang".
Funny how one badly written S. A article outrages everyone. They will spend time defending the company with very articulate comments. Yet, one poster has intentionally crashed the stock price 4 TIMES since Dec 11th and the gets thanked for his charts. The latest dump was July 20. He timed that one nice to go against the great phase 3 news.
3 times big drops immediately in price. One post was all he needed. The one time it slightly rose in May he posted 5 times in 2 weeks to finally get his drop. Give him credit for being relentless. Amazing how one group can control a lightly traded stock.
I guess Leo will get blamed until the chart dude and his minions loosen their grip from the neck of this company.
Hopefully up listing dampens the effect of these type of manipulators. These actions are hurting this company at the time.
This price with this PIPELINE is a shame.
Have a great night. Go CTIX, "eventually"
4 $ now. Chart dude won't allow that to happen..eom
Maybe his minions can drag the price below 3 dollars a share by close Friday. That will take the up listing talk off the table for the weekend.
It's easy BK.
1) chart dude spams the board. ( that's the signal )
2) Numerous posters thank him. ( sell orders go in at the open )
3) Bear posters show up. (R/S, no money, furniture depreciation become talking points )
4) Price drops immediately.( self fulfilling action ) See Dec 11, Jan 16 , May 28, July 20.
4) Weekends spent complaining about Leo and why stock price is so low.
It's that easy.
Really, Dec 11, Jan 16, May 28 and July 20th are the last 4 times I remember him posting. The results are obvious in all cases immediately. Please show where his posts have resulted in a rapid immediate increase in share price. I know the price is going down when he posts. Give him credit for being able to crash the price when he wants.
Over bought at 3 dollars a share with this pipeline...lol
Hope your right. GL..eom
They reference that non issue to scare people away. The chart dude with his followers dropped the price 22 cents yesterday and want more. He did the same crap Dec 11th when CTIX was at 4.80 and we all know what happened after that post. They are taken advantage of a lightly traded stock.
Tom Brady stated it perfectly yesterday about this person but got deleted.
Don't blame aspire. One post yesterday and many of us knew we were going down today. Happens every time.
LOL, funny but sadly true...eom
Funds are accumulating. They won't let it run away. Too many investors to fleece before they release the reigns. Rise yes, rapid no...IMO
Wake up to CTIX..Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
Company Reports Successful End-of-Phase 2 Meeting With FDA
BEVERLY, MA--(Marketwired - July 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has agreed to advancing brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
During a recently held End-of-Phase 2 Meeting, Cellceutix and the FDA discussed safety and efficacy data that support advancement into phase 3, as well as the basic elements of a phase 3 program. The planned phase 3 program would include two phase 3 ABSSSI studies, as required by FDA Guidance. In addition, the first study would include an interim analysis after a portion of the patients has been enrolled. This would provide an early assessment of both safety and efficacy. As part of the agreement, the Company would submit a Pediatric Study Plan (PSP) within 60 days of the End-of-Phase 2 Meeting.
Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer and leader of the team that met with the FDA, was pleased with the outcome of the meeting. "This was a collaborative meeting, and the FDA was extremely helpful in providing guidance on our clinical development program in ABSSSI. The plan for an interim analysis makes sense, as this is a brand new class of antibiotics."
Brilacidin is the lead compound in a new class of antibiotics known as the defensin-mimetics. These compounds mimic the host defense proteins of the innate immune system, and therefore, have both antibacterial and immunomodulatory properties. Brilacidin has been administered intravenously in over 400 subjects in phase 1 and phase 2, and is currently being evaluated in a phase 2 study as a topical rinse for the prevention and treatment of oral mucositis in cancer patients.
Brilacidin was granted Qualified Infectious Disease Product (QIDP) designation by the FDA in November 2014. The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act for the purpose of encouraging development of new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that brilacidin is now eligible for additional FDA incentives, including Fast Track designation and Priority Review for clinical development, and a five-year extension of market exclusivity.
CTIX NEWS....Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
Company Reports Successful End-of-Phase 2 Meeting With FDA
BEVERLY, MA--(Marketwired - July 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has agreed to advancing brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
During a recently held End-of-Phase 2 Meeting, Cellceutix and the FDA discussed safety and efficacy data that support advancement into phase 3, as well as the basic elements of a phase 3 program. The planned phase 3 program would include two phase 3 ABSSSI studies, as required by FDA Guidance. In addition, the first study would include an interim analysis after a portion of the patients has been enrolled. This would provide an early assessment of both safety and efficacy. As part of the agreement, the Company would submit a Pediatric Study Plan (PSP) within 60 days of the End-of-Phase 2 Meeting.
Dr. Daniel Jorgensen, Cellceutix's Chief Medical Officer and leader of the team that met with the FDA, was pleased with the outcome of the meeting. "This was a collaborative meeting, and the FDA was extremely helpful in providing guidance on our clinical development program in ABSSSI. The plan for an interim analysis makes sense, as this is a brand new class of antibiotics."
Brilacidin is the lead compound in a new class of antibiotics known as the defensin-mimetics. These compounds mimic the host defense proteins of the innate immune system, and therefore, have both antibacterial and immunomodulatory properties. Brilacidin has been administered intravenously in over 400 subjects in phase 1 and phase 2, and is currently being evaluated in a phase 2 study as a topical rinse for the prevention and treatment of oral mucositis in cancer patients.
Brilacidin was granted Qualified Infectious Disease Product (QIDP) designation by the FDA in November 2014. The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act for the purpose of encouraging development of new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that brilacidin is now eligible for additional FDA incentives, including Fast Track designation and Priority Review for clinical development, and a five-year extension of market exclusivity.
GO CTIX, GO LEOOOOoooo $$$$$$.eom
Me thinks there could be a method of madness to how Leo has handled the up listing. 2.5 million shares traded last week. I highly doubt retail buys was a major portion of that action. One fund has 2 million shares accumulated with another starting a small dabble. That's the ones we KNOW about at this time. I wonder how many institutions are accumulating extremely cheap shares since they were given notice of a certain NASDAQ up listing in the near future. A few months heads up would be appreciated by fund managers if they were interested buying into a future NASDAQ rising star that ALSO has a very high % of insider holdings.
There would be no down turn in price after up listing because of funds wanting cheap shares if they already filled up on the fools selling for pennies in the past months.
Can't wait for Monday..GO CTIX
How long before CTIX and it's management
are featured on the cover of one of the following publications , Forbes, Fortune, Harvard business revue, Economist or Bloomberg business week. I predict within 3 years.
Also, I will record the moment the prestigious CTIX gang rings the bell at 9:30.
Looking forward to good times.
Thanks CTIX.